Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on August 13, 2013. The filing announces the financial results for the quarter ended June 30, 2013. The full details of the results are contained in a press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text serves as a cover document referencing the results but does not contain specific numerical data. Consequently, the filing text does not provide clear values for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Operating Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements are referenced as being part of the press release in Exhibit 99.1.
Important Facts for Investor Verification
- Verify the correct registrant name: The filing is for OvaScience, Inc., despite the metadata request referencing Tempest Therapeutics, Inc.
- Locate and review Exhibit 99.1 (Press Release dated August 13, 2013) to obtain actual financial figures, as they are absent from the 8-K body text.
- Note that the information in this 8-K and its exhibit is not deemed "filed" under Section 18 of the Exchange Act, limiting liability protections for the disclosed data.